Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ad5-105K TB Vaccine in Adults
NCT06732583Phase 1Active, not recruiting
- Sponsor
- CanSino Biologics Inc.
- Start
- Nov 2025
- Primary completion
- Aug 2026
- Modality
- Prophylactic Vaccines, DNA Vaccines
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of Ad5-105K in Tuberculosis (TB) (4 arms), sponsored by CanSino Biologics Inc. Primary endpoint: Occurrence of solicited adverse events at 7 days. Started Nov 2025; status: active, not recruiting.
02
Drugs
Ad5-105K
03
Conditions
Tuberculosis (TB)
Beyond the preview
Go deeper on NCT06732583.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06732583.